Yinghui Lin

Statistics

Publications

Citations

725

H-Index

Active since

1992

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

United States Military Academy

Yinghui Lin is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in drug discovery, potency optimization, and pharmacology.

ORCID

Publications per year

1992–2017

Publications

MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition

Matthew Fell, Christian Mirescu, Kallol Basu et al. · Journal of Pharmacology and Experimental Therapeutics · 2015 · 337 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity

Jack D. Scott, Duane E. DeMong, Thomas J. Greshock et al. · Journal of Medicinal Chemistry · 2017 · 148 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16

Protein disulfide isomerase activity is released by activated platelets

K Chen, Yinghui Lin, TC Detwiler · Blood · 1992 · 102 citations · Full text

Medicine, Biochemistry, Molecular Biology +14

The JAMM motif of human deubiquitinase Poh1 is essential for cell viability

Melissa Gallery, Jonathan L. Blank, Yinghui Lin et al. · Molecular Cancer Therapeutics · 2007 · 75 citations

Life Sciences, Cell Biology, Molecular Biology +15

Acne patients frequently associated with abnormal plasma lipid profile

Jiang Hao, Chang Yi Li, Lü Zhou et al. · The Journal of Dermatology · 2015 · 46 citations

Medicine, Dermatology, Pathology +14

1–5 of 6